TY - JOUR
T1 - The impact of HPV genotypes on survival in HPV-positive oropharyngeal squamous cell carcinomas
T2 - a systematic review
AU - Skovvang, Anne
AU - Jensen, Jakob Schmidt
AU - Garset-Zamani, Martin
AU - Carlander, Amanda
AU - Grønhøj, Christian
AU - von Buchwald, Christian
PY - 2021/7
Y1 - 2021/7
N2 - BACKGROUND: Patients with HPV-positive (HPV+) oropharyngeal squamous cell carcinomas (OPSCCs) are known to have a better prognosis compared to patients with HPV-negative OPSCCs.AIMS/OBJECTIVES: To investigate the impact of specific HPV genotypes on survival in HPV + OPSCC.MATERIAL AND METHODS: A systematic search of PubMed and Embase for studies addressing the association between specific HPV genotypes and survival among patients with OPSCC was performed.RESULTS: Six studies (n = 1385 patients) published between 2013 and 2017 were included. Five studies (n = 1290 patients) found a better survival among HPV16 cases compared to other high-risk (HR) HPV genotypes (HPV 33, 18, 35, 31, 39, 52, 59, 45, 56, 67, 29, and 58), of which three studies (n = 933 patients) reached significant results. Two of these studies reported a five-year overall survival (OS) of 64.6% and 71.4% in HPV16 OPSCCs vs. 45.6% and 57.1% in HR non-HPV16 OPSCCs (p = .001 and p = .010, respectively), and the last study found a better OS among HPV16 cases with a hazard ratio (HR) of 0.35, 95%. CI [0.14;0.85], p = .02.CONCLUSIONS: Our findings indicate a favorable prognosis among patients with HPV16 OPSCC compared with HR non-HPV16 OPSCC. These results may be important when designing future trials and in the planning of follow-up regimes.
AB - BACKGROUND: Patients with HPV-positive (HPV+) oropharyngeal squamous cell carcinomas (OPSCCs) are known to have a better prognosis compared to patients with HPV-negative OPSCCs.AIMS/OBJECTIVES: To investigate the impact of specific HPV genotypes on survival in HPV + OPSCC.MATERIAL AND METHODS: A systematic search of PubMed and Embase for studies addressing the association between specific HPV genotypes and survival among patients with OPSCC was performed.RESULTS: Six studies (n = 1385 patients) published between 2013 and 2017 were included. Five studies (n = 1290 patients) found a better survival among HPV16 cases compared to other high-risk (HR) HPV genotypes (HPV 33, 18, 35, 31, 39, 52, 59, 45, 56, 67, 29, and 58), of which three studies (n = 933 patients) reached significant results. Two of these studies reported a five-year overall survival (OS) of 64.6% and 71.4% in HPV16 OPSCCs vs. 45.6% and 57.1% in HR non-HPV16 OPSCCs (p = .001 and p = .010, respectively), and the last study found a better OS among HPV16 cases with a hazard ratio (HR) of 0.35, 95%. CI [0.14;0.85], p = .02.CONCLUSIONS: Our findings indicate a favorable prognosis among patients with HPV16 OPSCC compared with HR non-HPV16 OPSCC. These results may be important when designing future trials and in the planning of follow-up regimes.
KW - genotype
KW - Human papillomaviurs
KW - oropharyngeal squamous cell carcinoma
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85107732726&partnerID=8YFLogxK
U2 - 10.1080/00016489.2021.1927173
DO - 10.1080/00016489.2021.1927173
M3 - Review
C2 - 34101529
SN - 0001-6489
VL - 141
SP - 724
EP - 728
JO - Acta Oto-Laryngologica
JF - Acta Oto-Laryngologica
IS - 7
ER -